UroCCR Database: French Research Network for Kidney Cancer -UroCCR (UroCCR)

May 27, 2026 updated by: University Hospital, Bordeaux

UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)

Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.

More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.

By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.

With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.

A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.

The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.

Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.

At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.

Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Belgium
      • Brussels, Belgium
        • Not yet recruiting
        • Hopital Universitaire de Bruxelles
        • Contact:
          • Thierry ROUMEGUERE, Pr
  • France
      • Angers, France, 49100
        • Recruiting
        • CHU Angers
        • Contact:
          • Pierre BIGOT, Pr
      • Bordeaux, France, 33076
        • Recruiting
        • CHU Bordeaux
        • Contact:
          • Jean-Christophe BERNHARD, Pr
      • Bordeaux, France
        • Recruiting
        • Clinique Tivoli-Ducos
        • Contact:
          • Clément MICHIELS, Dr
      • Cabestany, France
        • Recruiting
        • Polyclinique Médipôle Saint-Roch_Cabestany
        • Contact:
          • Pierre GIMEL, Dr
      • Caen, France
        • Recruiting
        • CHU caen
        • Contact:
          • Xavier TILLOU, Pr
      • Chalon-sur-Saône, France
        • Not yet recruiting
        • Centre hospitalier Chalon sur Saône
        • Contact:
          • Nicolas KOUTLIDIS, Dr
      • Clermont-Ferrand, France
        • Recruiting
        • CHU de Clermont-Ferrand
        • Contact:
          • Laurent GUY, Pr
      • Colmar, France
        • Not yet recruiting
        • Hôpitaux Civils de Colmar
        • Contact:
          • Jonathan THOUVENIN, Dr
      • Corbeil-Essonnes, France
        • Recruiting
        • Ch Sud Francilien
        • Contact:
          • Pietro GRANDE, Dr
      • Creil, France
        • Not yet recruiting
        • Groupe Hospitalier Public du Sud de l'Oise
        • Contact:
          • Fares KOSSEIFI, Dr
      • Créteil, France, 94010
        • Recruiting
        • CHU Henri Mondor - APHP
        • Contact:
          • Alexandre INGELS, Pr
      • Dijon, France
        • Recruiting
        • CHU de Dijon et CLCC Dijon
        • Contact:
          • Benjamin DELATTRE, Dr
      • Fontainebleau, France
        • Recruiting
        • CH du Sud Seine et Marne
        • Contact:
          • Karim BEN OTHMAN, Dr
      • Hénin-Beaumont, France
        • Not yet recruiting
        • Polyclinique d'Henin Beaumont
        • Contact:
          • Martin LORETTE, Dr
      • La Roche-sur-Yon, France
        • Not yet recruiting
        • Centre Hospitalier Départemental de Vendée
        • Contact:
          • Constance DEBOUDT-MACE, Dr
      • La Tronche, France, 38700
        • Recruiting
        • CHU Grenoble
        • Contact:
          • Jean-Luc DESCOTES, Pr
      • Le Mans, France
        • Recruiting
        • Pôle Santé Sud
        • Contact:
          • Olivier BELAS, Dr
      • Le Puy-en-Velay, France, 43000
        • Not yet recruiting
        • Clinique Bon Secours-ELSAN
        • Contact:
          • Marlène GUANDALINO, Dr
      • Levallois-Perret, France
        • Not yet recruiting
        • Hôpital Franco-Britannique,
        • Contact:
          • Caroline PETTENATI, Dr
      • Libourne, France
        • Recruiting
        • CH Libourne
        • Contact:
          • Benjamin ROUGET, Dr
      • Lille, France
        • Recruiting
        • Hôpital privé La Louvière
        • Contact:
          • Charles BALLEREAU, Dr
      • Lille, France, 59037
        • Recruiting
        • CHRU Lille - Centre Oscar Lambret
        • Contact:
          • Jonathan OLIVIER, Pr
      • Limoges, France, 87042
        • Recruiting
        • CHU Limoges
        • Contact:
          • Aurélien DESCAZEAUD
      • Longjumeau, France
        • Not yet recruiting
        • Clinique de l'Yvette
        • Contact:
          • Benjamin GABAY, Dr
      • Lyon, France, 69002
        • Recruiting
        • HCL Lyon
        • Contact:
          • Philippe PAPAREL, Pr
      • Marseille, France
        • Recruiting
        • APH Marseille
        • Contact:
          • Eric LECHEVALLIER, Pr
      • Marseille, France
        • Recruiting
        • Institut Paoli-Calmette
        • Contact:
          • Nicolas BRANGER, Dr
      • Meaux, France
        • Not yet recruiting
        • Grand Hôpital de l'Est Francilien
        • Contact:
          • Julien SARKIS, Dr
      • Metz, France
        • Not yet recruiting
        • Centre Hospitalier d' Annecy Genevois
        • Contact:
          • Arnoux VALENTIN, Dr
      • Mont-de-Marsan, France
        • Recruiting
        • CH Mont de Marsan
        • Contact:
          • Jean-Jacques PATARD, Pr
      • Montauban, France
        • Recruiting
        • Clinique Du Pont De Chaume
        • Contact:
          • Jérôme GAS, Dr
      • Montpellier, France
        • Not yet recruiting
        • CHU de Montpellier
        • Contact:
          • Rodolphe THURET, Dr
      • Nancy, France
        • Recruiting
        • CHRU de NANCY
        • Contact:
          • Pascal ESCHWEGE, Pr
      • Nantes, France
        • Recruiting
        • Chu de Nantes
        • Contact:
          • Stéphane DE VERGIE, Dr
      • Nice, France
        • Recruiting
        • Chu de Nice
        • Contact:
          • Matthieu DURAND, Pr
      • Nice, France
        • Recruiting
        • Clinique Saint George
        • Contact:
          • Alexandre MARSAUD, Dr
      • Nîmes, France
        • Recruiting
        • CHU de Nîmes
        • Contact:
          • Alexis FONTENIL, Dr
      • Orléans, France
        • Recruiting
        • CHU d'Orléans
        • Contact:
          • Nicolas BRICHART, DR
      • Paris, France
        • Not yet recruiting
        • Hopital saint Louis
        • Contact:
          • Sonia BEBANE, Dr
      • Paris, France
        • Not yet recruiting
        • Institut Mutualiste Montsouris
        • Contact:
          • Mostefa BENNAMOUN, Dr
      • Paris, France, 75013
        • Recruiting
        • CHU Kremlin Bicêtre - APHP
        • Contact:
          • Sébastien PARIER, Dr
      • Paris, France, 75014
        • Recruiting
        • CH St Joseph
        • Contact:
          • Xavier DURAND, Pr
      • Paris, France, 75015
        • Recruiting
        • Hôpital Européen Georges Pompidou - APHP
        • Contact:
          • François AUDENET, Dr
      • Paris, France
        • Recruiting
        • Hôpital Bichat -APHP
        • Contact:
          • Evangelos Xylinas, Dr
      • Paris, France
        • Recruiting
        • Hôpital Pitié Salpétrière - APHP
        • Contact:
          • Morgan ROUPRET, Pr
      • Paris, France
        • Recruiting
        • Hôpital Cochin Port-Royal - APHP
        • Contact:
          • Julien ANRACT, Dr
      • Paris, France
        • Recruiting
        • CHU Tenon - APHP
        • Contact:
          • Olivier TRAXER, Pr
      • Plérin, France
        • Recruiting
        • Hôpital Privé Des Côtes d'Armor
        • Contact:
          • Fabien BOULIERE, Dr
      • Poitiers, France
        • Recruiting
        • CHU Poitiers
        • Contact:
          • Maxime VALLEE, Dr
      • Périgueux, France
        • Recruiting
        • Polyclinique Francheville
        • Contact:
          • Richard MALLET, Dr
      • Quincy-sous-Sénart, France
        • Recruiting
        • Hôpital Privé Claude Galien
        • Contact:
          • Julien DEFONTAINES, Dr
      • Quint-Fonsegrives, France
        • Recruiting
        • Clinique La Croix Du Sud
        • Contact:
          • Jean-Baptiste BEAUVAL, Dr
      • Reims, France
        • Recruiting
        • Chu Reims
        • Contact:
          • Charlotte JONCOUR, Dr
      • Rennes, France, 35000
        • Recruiting
        • CHU Rennes - Centre Eugène Marquis
        • Contact:
          • Karim BENSALAH, Pr
      • Rouen, France, 76031
        • Recruiting
        • CHU Rouen
        • Contact:
          • Christian PFISTER, Pr
      • Saint-Etienne, France
        • Recruiting
        • CHU St-Etienne
        • Contact:
          • Lionel BADET, Pr
      • Saint-Herblain, France
        • Recruiting
        • Clinique Santé Atlantique de Nantes
        • Contact:
          • Quentin-Come LE CLERC, Dr
      • Saint-Herblain, France
        • Recruiting
        • Clinique Urologique Nantes Atlantis
        • Contact:
          • Lionel HOQUETIS, Dr
      • Saint-Martin-d'Hères, France
        • Recruiting
        • Clinique Belledonne
        • Contact:
          • Jean-Alexandre LONG, Pr
      • Strasbourg, France, 67000
        • Recruiting
        • CHU Strasbourg
        • Contact:
          • Hervé LANG, Pr
      • Strasbourg, France
        • Recruiting
        • ICANS
        • Contact:
          • Gabriel MALOUF, Pr
      • Toulouse, France
        • Recruiting
        • Clinique Pasteur
        • Contact:
          • Julien GUILLOTREAU, Dr
      • Toulouse, France, 31059
        • Recruiting
        • CHU Toulouse - Centre Claudius Régaud
        • Contact:
          • Nicolas DOUMERC, Dr
      • Tours, France
        • Recruiting
        • CHRU Tours
        • Contact:
          • Franck BRUYERE, Pr
      • Vandœuvre-lès-Nancy, France
        • Not yet recruiting
        • Institut de Cancérologie lorraine
        • Contact:
          • Sophie MARTIN, Dr
  • French Guiana
      • Kourou, French Guiana
        • Recruiting
        • Centre Hospitalier de Kourou
        • Contact:
          • Vincent RAVERY, Pr
  • Reunion
      • Saint-Denis, Reunion
        • Not yet recruiting
        • CHU Bellepierre
        • Contact:
          • Davidson SYPRE, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with Kidney cancer

Description

Inclusion Criteria:

  • Adult patient with kidney cancer
  • Patient with no opposition to collection of its data for the study

Exclusion Criteria: none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Patients
Adult patients with kidney cancer
Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Operative time, ,
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Blood loss
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Clinical scores
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Dosage of creatininemia to assess the renal function after surgery
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of creatininemia
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR to assess the renal function after surgery
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with Clavien's grading
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with urinary fistula rate
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with necessity for nephrectomy or re-exploration
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Safety and efficacy of medical treatment on kidney tumor size evolution
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Imaging data: tumor size evolution
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Safety and efficacy of medical treatment on biological parameters
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Biological parameters
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Progression of the tumor
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Imaging data: tumor location
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Bordeaux

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Jean-Christophe BERNHARD, PHU, University Hospital, Bordeaux

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2011

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2040

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2040

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 12, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 20, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 26, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 28, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CHUBX 2011/38

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Cancer

Clinical Trials on Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings